nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—MPO—Carboplatin—uterine cancer	0.266	0.652	CbGbCtD
Mesalazine—PTGS2—Etoposide—uterine cancer	0.0771	0.189	CbGbCtD
Mesalazine—PTGS1—Etoposide—uterine cancer	0.0651	0.16	CbGbCtD
Mesalazine—MPO—artery—uterine cancer	0.00547	0.0498	CbGeAlD
Mesalazine—PPARG—artery—uterine cancer	0.00485	0.0442	CbGeAlD
Mesalazine—CHUK—epithelium—uterine cancer	0.00435	0.0396	CbGeAlD
Mesalazine—CHUK—renal system—uterine cancer	0.00403	0.0367	CbGeAlD
Mesalazine—Salicylic acid—AKR1C1—uterine cancer	0.00394	1	CrCbGaD
Mesalazine—PTGS1—oviduct—uterine cancer	0.00392	0.0357	CbGeAlD
Mesalazine—PPARG—Teniposide—Etoposide—uterine cancer	0.00381	1	CbGdCrCtD
Mesalazine—IKBKB—myometrium—uterine cancer	0.00377	0.0343	CbGeAlD
Mesalazine—CHUK—female reproductive system—uterine cancer	0.00323	0.0294	CbGeAlD
Mesalazine—CHUK—female gonad—uterine cancer	0.00294	0.0268	CbGeAlD
Mesalazine—IKBKB—uterine cervix—uterine cancer	0.00293	0.0267	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—uterine cancer	0.00285	0.0259	CbGeAlD
Mesalazine—IKBKB—decidua—uterine cancer	0.00279	0.0254	CbGeAlD
Mesalazine—IKBKB—endometrium—uterine cancer	0.00265	0.0241	CbGeAlD
Mesalazine—PTGS1—artery—uterine cancer	0.00259	0.0236	CbGeAlD
Mesalazine—IKBKB—mammalian vulva—uterine cancer	0.00256	0.0233	CbGeAlD
Mesalazine—PTGS2—artery—uterine cancer	0.00248	0.0226	CbGeAlD
Mesalazine—IKBKB—uterus—uterine cancer	0.00244	0.0222	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—uterine cancer	0.00236	0.0215	CbGeAlD
Mesalazine—ALOX5—decidua—uterine cancer	0.00231	0.0211	CbGeAlD
Mesalazine—IKBKB—female reproductive system—uterine cancer	0.0022	0.02	CbGeAlD
Mesalazine—MPO—epithelium—uterine cancer	0.00207	0.0189	CbGeAlD
Mesalazine—IKBKB—female gonad—uterine cancer	0.002	0.0182	CbGeAlD
Mesalazine—IKBKB—vagina—uterine cancer	0.00199	0.0181	CbGeAlD
Mesalazine—MPO—renal system—uterine cancer	0.00192	0.0175	CbGeAlD
Mesalazine—CHUK—lymph node—uterine cancer	0.00189	0.0172	CbGeAlD
Mesalazine—PPARG—epithelium—uterine cancer	0.00184	0.0167	CbGeAlD
Mesalazine—ALOX5—female reproductive system—uterine cancer	0.00182	0.0166	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—uterine cancer	0.00177	0.0161	CbGeAlD
Mesalazine—PPARG—decidua—uterine cancer	0.00174	0.0158	CbGeAlD
Mesalazine—PPARG—renal system—uterine cancer	0.00171	0.0155	CbGeAlD
Mesalazine—ALOX5—female gonad—uterine cancer	0.00166	0.0151	CbGeAlD
Mesalazine—PPARG—mammalian vulva—uterine cancer	0.0016	0.0145	CbGeAlD
Mesalazine—PPARG—uterus—uterine cancer	0.00152	0.0138	CbGeAlD
Mesalazine—PPARG—female reproductive system—uterine cancer	0.00137	0.0124	CbGeAlD
Mesalazine—IKBKB—lymph node—uterine cancer	0.00128	0.0117	CbGeAlD
Mesalazine—PPARG—female gonad—uterine cancer	0.00124	0.0113	CbGeAlD
Mesalazine—PPARG—vagina—uterine cancer	0.00124	0.0113	CbGeAlD
Mesalazine—PTGS2—myometrium—uterine cancer	0.0012	0.0109	CbGeAlD
Mesalazine—ALOX5—lymph node—uterine cancer	0.00106	0.00969	CbGeAlD
Mesalazine—PTGS1—epithelium—uterine cancer	0.000983	0.00895	CbGeAlD
Mesalazine—PTGS1—uterine cervix—uterine cancer	0.000975	0.00888	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—uterine cancer	0.000947	0.00863	CbGeAlD
Mesalazine—PTGS2—epithelium—uterine cancer	0.00094	0.00856	CbGeAlD
Mesalazine—PTGS2—uterine cervix—uterine cancer	0.000932	0.00849	CbGeAlD
Mesalazine—PTGS1—renal system—uterine cancer	0.000912	0.00831	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—uterine cancer	0.000906	0.00825	CbGeAlD
Mesalazine—MPO—lymph node—uterine cancer	0.000901	0.0082	CbGeAlD
Mesalazine—PTGS1—endometrium—uterine cancer	0.000882	0.00803	CbGeAlD
Mesalazine—PTGS2—renal system—uterine cancer	0.000872	0.00794	CbGeAlD
Mesalazine—PTGS1—mammalian vulva—uterine cancer	0.000853	0.00777	CbGeAlD
Mesalazine—PTGS2—endometrium—uterine cancer	0.000843	0.00767	CbGeAlD
Mesalazine—PTGS1—uterus—uterine cancer	0.000813	0.0074	CbGeAlD
Mesalazine—PPARG—lymph node—uterine cancer	0.000799	0.00728	CbGeAlD
Mesalazine—PTGS2—uterus—uterine cancer	0.000777	0.00707	CbGeAlD
Mesalazine—PTGS1—female reproductive system—uterine cancer	0.00073	0.00665	CbGeAlD
Mesalazine—PTGS2—female reproductive system—uterine cancer	0.000698	0.00636	CbGeAlD
Mesalazine—PTGS1—female gonad—uterine cancer	0.000665	0.00605	CbGeAlD
Mesalazine—PTGS1—vagina—uterine cancer	0.000661	0.00602	CbGeAlD
Mesalazine—PTGS2—female gonad—uterine cancer	0.000635	0.00579	CbGeAlD
Mesalazine—PTGS2—vagina—uterine cancer	0.000631	0.00575	CbGeAlD
Mesalazine—PTGS1—lymph node—uterine cancer	0.000427	0.00389	CbGeAlD
Mesalazine—PTGS2—lymph node—uterine cancer	0.000408	0.00372	CbGeAlD
Mesalazine—Nasopharyngitis—Doxorubicin—uterine cancer	0.000134	0.000424	CcSEcCtD
Mesalazine—Pancytopenia—Epirubicin—uterine cancer	0.000133	0.000421	CcSEcCtD
Mesalazine—Hypotension—Etoposide—uterine cancer	0.000133	0.00042	CcSEcCtD
Mesalazine—Gastritis—Doxorubicin—uterine cancer	0.000133	0.00042	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000132	0.000418	CcSEcCtD
Mesalazine—Neutropenia—Epirubicin—uterine cancer	0.000131	0.000414	CcSEcCtD
Mesalazine—Dysuria—Epirubicin—uterine cancer	0.000131	0.000414	CcSEcCtD
Mesalazine—Abdominal distension—Doxorubicin—uterine cancer	0.00013	0.000413	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Epirubicin—uterine cancer	0.00013	0.000412	CcSEcCtD
Mesalazine—Dysphagia—Doxorubicin—uterine cancer	0.000129	0.00041	CcSEcCtD
Mesalazine—Asthma—Doxorubicin—uterine cancer	0.000129	0.00041	CcSEcCtD
Mesalazine—Influenza—Doxorubicin—uterine cancer	0.000129	0.00041	CcSEcCtD
Mesalazine—Pollakiuria—Epirubicin—uterine cancer	0.000129	0.000409	CcSEcCtD
Mesalazine—Eosinophilia—Doxorubicin—uterine cancer	0.000128	0.000406	CcSEcCtD
Mesalazine—Photosensitivity reaction—Epirubicin—uterine cancer	0.000128	0.000404	CcSEcCtD
Mesalazine—Paraesthesia—Etoposide—uterine cancer	0.000127	0.000404	CcSEcCtD
Mesalazine—Weight increased—Epirubicin—uterine cancer	0.000127	0.000403	CcSEcCtD
Mesalazine—Pancreatitis—Doxorubicin—uterine cancer	0.000127	0.000402	CcSEcCtD
Mesalazine—Weight decreased—Epirubicin—uterine cancer	0.000127	0.000401	CcSEcCtD
Mesalazine—Dyspnoea—Etoposide—uterine cancer	0.000127	0.000401	CcSEcCtD
Mesalazine—Somnolence—Etoposide—uterine cancer	0.000126	0.0004	CcSEcCtD
Mesalazine—Angina pectoris—Doxorubicin—uterine cancer	0.000126	0.000399	CcSEcCtD
Mesalazine—Pneumonia—Epirubicin—uterine cancer	0.000126	0.000397	CcSEcCtD
Mesalazine—Infestation—Epirubicin—uterine cancer	0.000125	0.000395	CcSEcCtD
Mesalazine—Infestation NOS—Epirubicin—uterine cancer	0.000125	0.000395	CcSEcCtD
Mesalazine—Vomiting—Dactinomycin—uterine cancer	0.000125	0.000395	CcSEcCtD
Mesalazine—Bronchitis—Doxorubicin—uterine cancer	0.000125	0.000394	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000124	0.000392	CcSEcCtD
Mesalazine—Rash—Dactinomycin—uterine cancer	0.000124	0.000392	CcSEcCtD
Mesalazine—Decreased appetite—Etoposide—uterine cancer	0.000123	0.000391	CcSEcCtD
Mesalazine—Pancytopenia—Doxorubicin—uterine cancer	0.000123	0.000389	CcSEcCtD
Mesalazine—Renal failure—Epirubicin—uterine cancer	0.000123	0.000388	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000123	0.000388	CcSEcCtD
Mesalazine—Fatigue—Etoposide—uterine cancer	0.000122	0.000387	CcSEcCtD
Mesalazine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000122	0.000387	CcSEcCtD
Mesalazine—Stomatitis—Epirubicin—uterine cancer	0.000122	0.000385	CcSEcCtD
Mesalazine—Jaundice—Epirubicin—uterine cancer	0.000122	0.000385	CcSEcCtD
Mesalazine—Pain—Etoposide—uterine cancer	0.000121	0.000384	CcSEcCtD
Mesalazine—Constipation—Etoposide—uterine cancer	0.000121	0.000384	CcSEcCtD
Mesalazine—Urinary tract infection—Epirubicin—uterine cancer	0.000121	0.000384	CcSEcCtD
Mesalazine—Conjunctivitis—Epirubicin—uterine cancer	0.000121	0.000384	CcSEcCtD
Mesalazine—Neutropenia—Doxorubicin—uterine cancer	0.000121	0.000383	CcSEcCtD
Mesalazine—Dysuria—Doxorubicin—uterine cancer	0.000121	0.000383	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.00012	0.000381	CcSEcCtD
Mesalazine—Sweating—Epirubicin—uterine cancer	0.00012	0.000379	CcSEcCtD
Mesalazine—Pollakiuria—Doxorubicin—uterine cancer	0.00012	0.000379	CcSEcCtD
Mesalazine—Haematuria—Epirubicin—uterine cancer	0.000119	0.000377	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000118	0.000374	CcSEcCtD
Mesalazine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000118	0.000374	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—uterine cancer	0.000118	0.000373	CcSEcCtD
Mesalazine—Epistaxis—Epirubicin—uterine cancer	0.000118	0.000373	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—uterine cancer	0.000117	0.000371	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—uterine cancer	0.000117	0.000371	CcSEcCtD
Mesalazine—Feeling abnormal—Etoposide—uterine cancer	0.000117	0.00037	CcSEcCtD
Mesalazine—Nausea—Dactinomycin—uterine cancer	0.000117	0.000369	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—uterine cancer	0.000116	0.000369	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—uterine cancer	0.000116	0.000368	CcSEcCtD
Mesalazine—Gastrointestinal pain—Etoposide—uterine cancer	0.000116	0.000368	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—uterine cancer	0.000115	0.000365	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—uterine cancer	0.000115	0.000365	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000114	0.000362	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—uterine cancer	0.000114	0.000359	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000113	0.000358	CcSEcCtD
Mesalazine—Urticaria—Etoposide—uterine cancer	0.000113	0.000357	CcSEcCtD
Mesalazine—Haemoglobin—Epirubicin—uterine cancer	0.000113	0.000356	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—uterine cancer	0.000113	0.000356	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—uterine cancer	0.000113	0.000356	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—uterine cancer	0.000112	0.000356	CcSEcCtD
Mesalazine—Body temperature increased—Etoposide—uterine cancer	0.000112	0.000355	CcSEcCtD
Mesalazine—Abdominal pain—Etoposide—uterine cancer	0.000112	0.000355	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—uterine cancer	0.000112	0.000355	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—uterine cancer	0.000112	0.000355	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—uterine cancer	0.000112	0.000355	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—uterine cancer	0.000112	0.000355	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—uterine cancer	0.000111	0.000352	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—uterine cancer	0.000111	0.00035	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—uterine cancer	0.000111	0.00035	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—uterine cancer	0.00011	0.000349	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—uterine cancer	0.00011	0.000348	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—uterine cancer	0.00011	0.000348	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—uterine cancer	0.00011	0.000348	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000109	0.000346	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—uterine cancer	0.000109	0.000345	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—uterine cancer	0.000108	0.000343	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—uterine cancer	0.000108	0.000341	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—uterine cancer	0.000106	0.000335	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—uterine cancer	0.000105	0.000331	CcSEcCtD
Mesalazine—Hypersensitivity—Etoposide—uterine cancer	0.000105	0.000331	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—uterine cancer	0.000104	0.000331	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—uterine cancer	0.000104	0.00033	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—uterine cancer	0.000104	0.000329	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—uterine cancer	0.000104	0.000329	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—uterine cancer	0.000104	0.000328	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—uterine cancer	0.000104	0.000328	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—uterine cancer	0.000103	0.000326	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000102	0.000324	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—uterine cancer	0.000102	0.000323	CcSEcCtD
Mesalazine—Asthenia—Etoposide—uterine cancer	0.000102	0.000322	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000102	0.000322	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—uterine cancer	0.000102	0.000322	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—uterine cancer	0.000102	0.000322	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—uterine cancer	0.000101	0.00032	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—uterine cancer	0.000101	0.00032	CcSEcCtD
Mesalazine—Chills—Epirubicin—uterine cancer	0.000101	0.000318	CcSEcCtD
Mesalazine—Pruritus—Etoposide—uterine cancer	0.0001	0.000318	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—uterine cancer	9.9e-05	0.000313	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—uterine cancer	9.81e-05	0.000311	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—uterine cancer	9.8e-05	0.00031	CcSEcCtD
Mesalazine—Erythema—Epirubicin—uterine cancer	9.75e-05	0.000309	CcSEcCtD
Mesalazine—Diarrhoea—Etoposide—uterine cancer	9.71e-05	0.000308	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—uterine cancer	9.69e-05	0.000307	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—uterine cancer	9.66e-05	0.000306	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—uterine cancer	9.62e-05	0.000305	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—uterine cancer	9.61e-05	0.000304	CcSEcCtD
Mesalazine—Tension—Epirubicin—uterine cancer	9.57e-05	0.000303	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—uterine cancer	9.55e-05	0.000302	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—uterine cancer	9.47e-05	0.0003	CcSEcCtD
Mesalazine—Back pain—Epirubicin—uterine cancer	9.43e-05	0.000299	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—uterine cancer	9.4e-05	0.000298	CcSEcCtD
Mesalazine—Dizziness—Etoposide—uterine cancer	9.39e-05	0.000297	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—uterine cancer	9.38e-05	0.000297	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—uterine cancer	9.36e-05	0.000296	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—uterine cancer	9.34e-05	0.000296	CcSEcCtD
Mesalazine—Chills—Doxorubicin—uterine cancer	9.3e-05	0.000294	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—uterine cancer	9.19e-05	0.000291	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—uterine cancer	9.16e-05	0.00029	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—uterine cancer	9.08e-05	0.000287	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—uterine cancer	9.05e-05	0.000286	CcSEcCtD
Mesalazine—Vomiting—Etoposide—uterine cancer	9.03e-05	0.000286	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—uterine cancer	9.02e-05	0.000286	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—uterine cancer	9.01e-05	0.000285	CcSEcCtD
Mesalazine—Rash—Etoposide—uterine cancer	8.95e-05	0.000283	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—uterine cancer	8.94e-05	0.000283	CcSEcCtD
Mesalazine—Headache—Etoposide—uterine cancer	8.89e-05	0.000282	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—uterine cancer	8.89e-05	0.000281	CcSEcCtD
Mesalazine—Tension—Doxorubicin—uterine cancer	8.85e-05	0.00028	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—uterine cancer	8.84e-05	0.00028	CcSEcCtD
Mesalazine—Malaise—Epirubicin—uterine cancer	8.79e-05	0.000278	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—uterine cancer	8.76e-05	0.000277	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—uterine cancer	8.76e-05	0.000277	CcSEcCtD
Mesalazine—Syncope—Epirubicin—uterine cancer	8.75e-05	0.000277	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—uterine cancer	8.73e-05	0.000276	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—uterine cancer	8.73e-05	0.000276	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—uterine cancer	8.68e-05	0.000275	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—uterine cancer	8.62e-05	0.000273	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—uterine cancer	8.57e-05	0.000271	CcSEcCtD
Mesalazine—Cough—Epirubicin—uterine cancer	8.51e-05	0.000269	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—uterine cancer	8.5e-05	0.000269	CcSEcCtD
Mesalazine—Nausea—Etoposide—uterine cancer	8.43e-05	0.000267	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—uterine cancer	8.42e-05	0.000267	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—uterine cancer	8.37e-05	0.000265	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—uterine cancer	8.34e-05	0.000264	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—uterine cancer	8.3e-05	0.000263	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—uterine cancer	8.3e-05	0.000263	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—uterine cancer	8.3e-05	0.000263	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—uterine cancer	8.27e-05	0.000262	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	8.25e-05	0.000261	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—uterine cancer	8.2e-05	0.00026	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—uterine cancer	8.14e-05	0.000258	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—uterine cancer	8.12e-05	0.000257	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—uterine cancer	8.11e-05	0.000257	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—uterine cancer	8.09e-05	0.000256	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—uterine cancer	8.08e-05	0.000256	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—uterine cancer	8.02e-05	0.000254	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—uterine cancer	7.97e-05	0.000252	CcSEcCtD
Mesalazine—Oedema—Epirubicin—uterine cancer	7.96e-05	0.000252	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—uterine cancer	7.96e-05	0.000252	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—uterine cancer	7.93e-05	0.000251	CcSEcCtD
Mesalazine—Infection—Epirubicin—uterine cancer	7.91e-05	0.00025	CcSEcCtD
Mesalazine—Cough—Doxorubicin—uterine cancer	7.87e-05	0.000249	CcSEcCtD
Mesalazine—Shock—Epirubicin—uterine cancer	7.83e-05	0.000248	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—uterine cancer	7.8e-05	0.000247	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—uterine cancer	7.79e-05	0.000247	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—uterine cancer	7.79e-05	0.000247	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—uterine cancer	7.77e-05	0.000246	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—uterine cancer	7.73e-05	0.000245	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—uterine cancer	7.69e-05	0.000244	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—uterine cancer	7.68e-05	0.000243	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—uterine cancer	7.68e-05	0.000243	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—uterine cancer	7.68e-05	0.000243	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—uterine cancer	7.66e-05	0.000242	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	7.63e-05	0.000241	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—uterine cancer	7.59e-05	0.00024	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—uterine cancer	7.59e-05	0.00024	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—uterine cancer	7.51e-05	0.000238	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—uterine cancer	7.44e-05	0.000235	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—uterine cancer	7.43e-05	0.000235	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—uterine cancer	7.36e-05	0.000233	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—uterine cancer	7.36e-05	0.000233	CcSEcCtD
Mesalazine—Infection—Doxorubicin—uterine cancer	7.32e-05	0.000232	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—uterine cancer	7.25e-05	0.00023	CcSEcCtD
Mesalazine—Shock—Doxorubicin—uterine cancer	7.25e-05	0.000229	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—uterine cancer	7.22e-05	0.000229	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—uterine cancer	7.21e-05	0.000228	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—uterine cancer	7.2e-05	0.000228	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—uterine cancer	7.19e-05	0.000228	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—uterine cancer	7.15e-05	0.000226	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—uterine cancer	7.15e-05	0.000226	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—uterine cancer	7.12e-05	0.000225	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—uterine cancer	7.1e-05	0.000225	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—uterine cancer	7.08e-05	0.000224	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—uterine cancer	7.02e-05	0.000222	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—uterine cancer	7.01e-05	0.000222	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—uterine cancer	6.92e-05	0.000219	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—uterine cancer	6.88e-05	0.000218	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—uterine cancer	6.87e-05	0.000218	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—uterine cancer	6.86e-05	0.000217	CcSEcCtD
Mesalazine—Constipation—Epirubicin—uterine cancer	6.81e-05	0.000215	CcSEcCtD
Mesalazine—Pain—Epirubicin—uterine cancer	6.81e-05	0.000215	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	6.71e-05	0.000212	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—uterine cancer	6.66e-05	0.000211	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—uterine cancer	6.61e-05	0.000209	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—uterine cancer	6.57e-05	0.000208	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—uterine cancer	6.56e-05	0.000208	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—uterine cancer	6.55e-05	0.000207	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—uterine cancer	6.51e-05	0.000206	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—uterine cancer	6.48e-05	0.000205	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—uterine cancer	6.4e-05	0.000203	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—uterine cancer	6.36e-05	0.000201	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—uterine cancer	6.35e-05	0.000201	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—uterine cancer	6.32e-05	0.0002	CcSEcCtD
Mesalazine—Pain—Doxorubicin—uterine cancer	6.3e-05	0.000199	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—uterine cancer	6.3e-05	0.000199	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—uterine cancer	6.29e-05	0.000199	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—uterine cancer	6.29e-05	0.000199	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—uterine cancer	6.07e-05	0.000192	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—uterine cancer	6.02e-05	0.000191	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—uterine cancer	5.86e-05	0.000186	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—uterine cancer	5.85e-05	0.000185	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—uterine cancer	5.82e-05	0.000184	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—uterine cancer	5.82e-05	0.000184	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—uterine cancer	5.71e-05	0.000181	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—uterine cancer	5.63e-05	0.000178	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—uterine cancer	5.45e-05	0.000172	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—uterine cancer	5.43e-05	0.000172	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	5.4e-05	0.000341	CbGpPWpGaD
Mesalazine—CHUK—Disease—FBXW7—uterine cancer	5.4e-05	0.000341	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—AKT1—uterine cancer	5.39e-05	0.000341	CbGpPWpGaD
Mesalazine—IKBKB—Insulin Signaling—AKT1—uterine cancer	5.35e-05	0.000338	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—AKT1—uterine cancer	5.35e-05	0.000338	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—AKT1—uterine cancer	5.32e-05	0.000336	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKR1B1—uterine cancer	5.32e-05	0.000336	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—STAR—uterine cancer	5.32e-05	0.000336	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FBXW7—uterine cancer	5.3e-05	0.000335	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NRAS—uterine cancer	5.29e-05	0.000335	CbGpPWpGaD
Mesalazine—Asthenia—Doxorubicin—uterine cancer	5.28e-05	0.000167	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—uterine cancer	5.28e-05	0.000334	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	5.26e-05	0.000333	CbGpPWpGaD
Mesalazine—Dizziness—Epirubicin—uterine cancer	5.26e-05	0.000167	CcSEcCtD
Mesalazine—PTGS1—Metabolism—POLD1—uterine cancer	5.26e-05	0.000332	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.26e-05	0.000332	CbGpPWpGaD
Mesalazine—Pruritus—Doxorubicin—uterine cancer	5.21e-05	0.000165	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—NRAS—uterine cancer	5.2e-05	0.000329	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—ERBB2—uterine cancer	5.19e-05	0.000328	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—uterine cancer	5.17e-05	0.000327	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—uterine cancer	5.17e-05	0.000327	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—AKT1—uterine cancer	5.14e-05	0.000325	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.12e-05	0.000324	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—MTHFR—uterine cancer	5.11e-05	0.000323	CbGpPWpGaD
Mesalazine—Vomiting—Epirubicin—uterine cancer	5.06e-05	0.00016	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—uterine cancer	5.04e-05	0.000159	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—AKT1—uterine cancer	5.04e-05	0.000318	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—KRAS—uterine cancer	5.02e-05	0.000318	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.02e-05	0.000317	CbGpPWpGaD
Mesalazine—Rash—Epirubicin—uterine cancer	5.02e-05	0.000159	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—uterine cancer	5.01e-05	0.000159	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—AKR1C1—uterine cancer	5e-05	0.000316	CbGpPWpGaD
Mesalazine—Headache—Epirubicin—uterine cancer	4.99e-05	0.000158	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—KRAS—uterine cancer	4.94e-05	0.000312	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	4.93e-05	0.000312	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKR1C1—uterine cancer	4.92e-05	0.000311	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDH1—uterine cancer	4.9e-05	0.00031	CbGpPWpGaD
Mesalazine—Dizziness—Doxorubicin—uterine cancer	4.87e-05	0.000154	CcSEcCtD
Mesalazine—PPARG—Gene Expression—CDKN2B—uterine cancer	4.85e-05	0.000307	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	4.82e-05	0.000305	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SOCS3—uterine cancer	4.79e-05	0.000303	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	4.75e-05	0.0003	CbGpPWpGaD
Mesalazine—Nausea—Epirubicin—uterine cancer	4.73e-05	0.00015	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—uterine cancer	4.68e-05	0.000148	CcSEcCtD
Mesalazine—PTGS2—Disease—AKR1C1—uterine cancer	4.66e-05	0.000295	CbGpPWpGaD
Mesalazine—Rash—Doxorubicin—uterine cancer	4.64e-05	0.000147	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—uterine cancer	4.64e-05	0.000147	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	4.62e-05	0.000292	CbGpPWpGaD
Mesalazine—Headache—Doxorubicin—uterine cancer	4.61e-05	0.000146	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—AKT1—uterine cancer	4.57e-05	0.000289	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—KRAS—uterine cancer	4.56e-05	0.000288	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CTNNB1—uterine cancer	4.54e-05	0.000287	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—PIK3CA—uterine cancer	4.54e-05	0.000287	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.5e-05	0.000285	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KRAS—uterine cancer	4.48e-05	0.000283	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDH1—uterine cancer	4.44e-05	0.000281	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SMAD3—uterine cancer	4.43e-05	0.00028	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—RRM2—uterine cancer	4.38e-05	0.000277	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—uterine cancer	4.37e-05	0.000138	CcSEcCtD
Mesalazine—IKBKB—Immune System—SOCS3—uterine cancer	4.34e-05	0.000274	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ERBB2—uterine cancer	4.3e-05	0.000272	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—uterine cancer	4.27e-05	0.00027	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—DCN—uterine cancer	4.25e-05	0.000269	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKR1C3—uterine cancer	4.24e-05	0.000268	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN2B—uterine cancer	4.23e-05	0.000267	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EP300—uterine cancer	4.22e-05	0.000267	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP19A1—uterine cancer	4.21e-05	0.000266	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—STK11—uterine cancer	4.21e-05	0.000266	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—uterine cancer	4.2e-05	0.000265	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	4.19e-05	0.000265	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POLD1—uterine cancer	4.17e-05	0.000264	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PGR—uterine cancer	4.13e-05	0.000261	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ERBB2—uterine cancer	4.13e-05	0.000261	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—PIK3CA—uterine cancer	4.11e-05	0.00026	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.04e-05	0.000255	CbGpPWpGaD
Mesalazine—PTGS2—Disease—DCN—uterine cancer	4.03e-05	0.000255	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP11A1—uterine cancer	4.01e-05	0.000253	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—uterine cancer	4e-05	0.000253	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FGFR2—uterine cancer	3.99e-05	0.000252	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CDKN1B—uterine cancer	3.98e-05	0.000252	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.95e-05	0.00025	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—NRAS—uterine cancer	3.95e-05	0.00025	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—YWHAE—uterine cancer	3.94e-05	0.000249	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKR1C1—uterine cancer	3.9e-05	0.000247	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ERBB2—uterine cancer	3.9e-05	0.000247	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—uterine cancer	3.87e-05	0.000245	CbGpPWpGaD
Mesalazine—CHUK—Disease—SMAD3—uterine cancer	3.86e-05	0.000244	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKR1C3—uterine cancer	3.85e-05	0.000243	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDKN1B—uterine cancer	3.83e-05	0.000242	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—uterine cancer	3.81e-05	0.000241	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKR1C3—uterine cancer	3.79e-05	0.000239	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FBXW7—uterine cancer	3.78e-05	0.000239	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.77e-05	0.000238	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CTNNB1—uterine cancer	3.76e-05	0.000238	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PGR—uterine cancer	3.75e-05	0.000237	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERBB2—uterine cancer	3.75e-05	0.000237	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.71e-05	0.000235	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—AKT1—uterine cancer	3.71e-05	0.000234	CbGpPWpGaD
Mesalazine—CHUK—Disease—FGFR2—uterine cancer	3.68e-05	0.000233	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PTEN—uterine cancer	3.67e-05	0.000232	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FGFR2—uterine cancer	3.62e-05	0.000229	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ESR1—uterine cancer	3.62e-05	0.000229	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CDKN1B—uterine cancer	3.61e-05	0.000228	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.59e-05	0.000227	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKR1C3—uterine cancer	3.59e-05	0.000227	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—YWHAE—uterine cancer	3.58e-05	0.000226	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTHFR—uterine cancer	3.55e-05	0.000224	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—uterine cancer	3.52e-05	0.000223	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EP300—uterine cancer	3.5e-05	0.000221	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HMGA1—uterine cancer	3.5e-05	0.000221	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—RRM2—uterine cancer	3.48e-05	0.00022	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1B—uterine cancer	3.47e-05	0.000219	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FBXW7—uterine cancer	3.43e-05	0.000217	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CTNNB1—uterine cancer	3.41e-05	0.000216	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—uterine cancer	3.4e-05	0.000215	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—DCN—uterine cancer	3.38e-05	0.000214	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—uterine cancer	3.36e-05	0.000212	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—uterine cancer	3.33e-05	0.00021	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STK11—uterine cancer	3.3e-05	0.000209	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NRAS—uterine cancer	3.27e-05	0.000207	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FBXW7—uterine cancer	3.2e-05	0.000202	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—uterine cancer	3.19e-05	0.000202	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP11A1—uterine cancer	3.18e-05	0.000201	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EP300—uterine cancer	3.17e-05	0.000201	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—uterine cancer	3.16e-05	0.0002	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NRAS—uterine cancer	3.14e-05	0.000199	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SOCS3—uterine cancer	3.09e-05	0.000196	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.03e-05	0.000192	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKR1C3—uterine cancer	3.01e-05	0.00019	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STK11—uterine cancer	3e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—uterine cancer	2.97e-05	0.000188	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NRAS—uterine cancer	2.97e-05	0.000188	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN2B—uterine cancer	2.96e-05	0.000187	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—STK11—uterine cancer	2.95e-05	0.000186	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP19A1—uterine cancer	2.95e-05	0.000186	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—uterine cancer	2.89e-05	0.000183	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1R—uterine cancer	2.88e-05	0.000182	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NRAS—uterine cancer	2.85e-05	0.00018	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—uterine cancer	2.84e-05	0.00018	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—uterine cancer	2.82e-05	0.000178	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SOCS3—uterine cancer	2.81e-05	0.000177	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.79e-05	0.000176	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.77e-05	0.000175	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—EP300—uterine cancer	2.71e-05	0.000171	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—uterine cancer	2.71e-05	0.000171	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SMAD3—uterine cancer	2.71e-05	0.000171	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—uterine cancer	2.69e-05	0.00017	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN2B—uterine cancer	2.69e-05	0.00017	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.64e-05	0.000167	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1R—uterine cancer	2.61e-05	0.000165	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—uterine cancer	2.59e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR2—uterine cancer	2.58e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—uterine cancer	2.55e-05	0.000161	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—uterine cancer	2.55e-05	0.000161	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN2B—uterine cancer	2.51e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—uterine cancer	2.51e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—uterine cancer	2.49e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—uterine cancer	2.45e-05	0.000155	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SMAD3—uterine cancer	2.45e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—uterine cancer	2.39e-05	0.000151	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—uterine cancer	2.35e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—STK11—uterine cancer	2.34e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP19A1—uterine cancer	2.34e-05	0.000148	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR2—uterine cancer	2.34e-05	0.000148	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1B—uterine cancer	2.32e-05	0.000147	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—uterine cancer	2.31e-05	0.000146	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—uterine cancer	2.3e-05	0.000145	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SMAD3—uterine cancer	2.29e-05	0.000145	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—uterine cancer	2.27e-05	0.000144	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—uterine cancer	2.25e-05	0.000142	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—uterine cancer	2.22e-05	0.00014	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—uterine cancer	2.21e-05	0.00014	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.2e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTNNB1—uterine cancer	2.19e-05	0.000139	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR2—uterine cancer	2.18e-05	0.000138	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—uterine cancer	2.17e-05	0.000137	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—uterine cancer	2.14e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—uterine cancer	2.14e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—uterine cancer	2.11e-05	0.000134	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—uterine cancer	2.1e-05	0.000133	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—uterine cancer	2.1e-05	0.000133	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.1e-05	0.000132	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—uterine cancer	2.09e-05	0.000132	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EP300—uterine cancer	2.04e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—uterine cancer	2.03e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Disease—CTNNB1—uterine cancer	2.02e-05	0.000128	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—uterine cancer	2.01e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—uterine cancer	2e-05	0.000127	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTNNB1—uterine cancer	1.99e-05	0.000126	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—uterine cancer	1.97e-05	0.000125	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.95e-05	0.000123	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—uterine cancer	1.94e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—uterine cancer	1.94e-05	0.000122	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—uterine cancer	1.92e-05	0.000121	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—uterine cancer	1.91e-05	0.000121	CbGpPWpGaD
Mesalazine—CHUK—Disease—EP300—uterine cancer	1.88e-05	0.000119	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EP300—uterine cancer	1.85e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—uterine cancer	1.84e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—uterine cancer	1.76e-05	0.000111	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—uterine cancer	1.76e-05	0.000111	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—uterine cancer	1.76e-05	0.000111	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—uterine cancer	1.76e-05	0.000111	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—uterine cancer	1.73e-05	0.000109	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—EP300—uterine cancer	1.68e-05	0.000106	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—uterine cancer	1.64e-05	0.000104	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—uterine cancer	1.64e-05	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—uterine cancer	1.62e-05	0.000102	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.55e-05	9.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—uterine cancer	1.54e-05	9.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—uterine cancer	1.51e-05	9.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—uterine cancer	1.51e-05	9.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—uterine cancer	1.5e-05	9.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—uterine cancer	1.49e-05	9.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—uterine cancer	1.47e-05	9.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CTNNB1—uterine cancer	1.42e-05	8.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—uterine cancer	1.39e-05	8.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—uterine cancer	1.39e-05	8.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—uterine cancer	1.39e-05	8.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—uterine cancer	1.38e-05	8.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—uterine cancer	1.37e-05	8.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—uterine cancer	1.37e-05	8.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—uterine cancer	1.36e-05	8.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EP300—uterine cancer	1.32e-05	8.33e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—uterine cancer	1.3e-05	8.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—uterine cancer	1.29e-05	8.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CTNNB1—uterine cancer	1.29e-05	8.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—uterine cancer	1.27e-05	8.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—uterine cancer	1.26e-05	7.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—uterine cancer	1.25e-05	7.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—uterine cancer	1.25e-05	7.89e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—uterine cancer	1.24e-05	7.85e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—uterine cancer	1.23e-05	7.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—uterine cancer	1.23e-05	7.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—uterine cancer	1.23e-05	7.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CTNNB1—uterine cancer	1.2e-05	7.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EP300—uterine cancer	1.19e-05	7.55e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—EP300—uterine cancer	1.18e-05	7.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—uterine cancer	1.17e-05	7.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—uterine cancer	1.14e-05	7.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—uterine cancer	1.13e-05	7.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—uterine cancer	1.12e-05	7.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—uterine cancer	1.12e-05	7.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EP300—uterine cancer	1.11e-05	7.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—uterine cancer	1.06e-05	6.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—uterine cancer	1.04e-05	6.59e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—uterine cancer	1.01e-05	6.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—uterine cancer	9.79e-06	6.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—uterine cancer	9.75e-06	6.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—uterine cancer	9.62e-06	6.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—uterine cancer	9.43e-06	5.96e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—EP300—uterine cancer	9.33e-06	5.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—uterine cancer	9.02e-06	5.7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—uterine cancer	8.97e-06	5.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—uterine cancer	8.84e-06	5.59e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—uterine cancer	8.7e-06	5.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—uterine cancer	8.55e-06	5.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—uterine cancer	8.24e-06	5.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—uterine cancer	8.18e-06	5.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—uterine cancer	7.96e-06	5.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—uterine cancer	7.63e-06	4.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—uterine cancer	7.22e-06	4.56e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—uterine cancer	7.11e-06	4.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—uterine cancer	6.9e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—uterine cancer	6.74e-06	4.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—uterine cancer	5.64e-06	3.57e-05	CbGpPWpGaD
